"This collaboration is mutually beneficial to both PCT and ATMI, as we each have specialized knowledge in our respective spheres of expertise that will ultimately benefit our clients and this emerging industry," said Senior Vice President and General Manager of ATMI LifeSciences, Mario Philips. "Our collaboration will allow us to share resources and information, and take advantage of new opportunities for business development to the benefit of our customers."
"NeoStem and its subsidiaries continue to grow and expand the businesses through strategic partnerships, such as with ATMI. We believe these partnerships are critical to remaining at the forefront of innovation through the utilization of new technologies that will enhance efficiencies and cost-effective high quality manufacturing," said Dr. Robin L. Smith, Chairman and CEO of NeoStem.
PCT, a wholly owned subsidiary of NeoStem, Inc., is a leading contract development and manufacturing organization in the cellular therapy industry. Since 1997 PCT has provided pre-clinical and clinical current Good Manufacturing Practice ("cGMP") development and manufacturing services to over 100 clients, advancing regenerative medicine product candidates from the development stage all the way through to human testing. PCT has two cGMP-compliant, state-of-the art facilities in New Jersey and California to serve the cell therapy industry and offers manufacturing of cell therapy-based products, product and innovative process development, cell and tissue processing, regulatory support, storage, distribution and delivery and consulting services.
NeoStem, Inc. ("NeoStem" or the "Company") is a leader in the emerging cellular therapy industry. The Company's business model includes the development of novel proprietary cell therapy products as well as operating PCT, a contract development and manufacturing organization providing services to others in the regenerative medicine industry. The combination of a therapeutic development business and revenue-generating service provider business provides the Company with capabilities for cost effective in-house product development and immediate revenue and cash flow generation.
About ATMI LifeSciences
ATMI LifeSciences is an acknowledged technology leader in the field of single-use bioprocess systems and consumables for the pharmaceutical and biopharmaceutical industries. Its innovative, market-leading portfolio of custom-engineered, flexible packaging solutions, single-use storage systems, mixers and bioreactors is driving bioprocess efficiency and delivering value for biopharmaceutical companies around the world.
ATMI, Inc. is a global provider of specialty semiconductor materials, and safe, high-purity materials handling and delivery solutions designed to increase process efficiencies for the microelectronics, life sciences, and other industries.
ATMI, Integrity and Xpansion are trademarks or registered trademarks of Advanced Technology Materials, Inc. in the U.S., other countries, or both.